title: Trends in the treatment of orthopaedic prosthetic infections.
abstract: The most commonly used therapy for prosthetic joint infection is a two-stage prosthetic exchange separated by 6 weeks of intravenous antibiotic therapy. This often results in long periods of hospitalization, morbidity, severe functional impairment and sometimes increased mortality. Therefore novel and challenging therapeutic approaches have been attempted, particularly in hip prosthetic infection. This includes, whenever possible, according to the type of microorganism, antibacterial susceptibility and clinical presentation (including age and comorbidities): (i) less aggressive surgical techniques (debridement and prosthesis retention, or re-implantation with a single-stage exchange arthroplasty); and (ii) antibiotic combinations active against biofilm-associated bacteria, including rifampicin (particularly with quinolones) with excellent bio-availability which allow prolonged and efficient oral therapy.
authors.affiliation: Orthopaedic Clinic, Geneva University Hospital, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland.
authors.forename: Louis
authors.initials: L
authors.lastname: Bernard
authors.forename: Pierre
authors.initials: P
authors.lastname: Hoffmeyer
authors.forename: Mathieu
authors.initials: M
authors.lastname: Assal
authors.forename: Pierre
authors.initials: P
authors.lastname: Vaudaux
authors.forename: Jacques
authors.initials: J
authors.lastname: Schrenzel
authors.forename: Daniel
authors.initials: D
authors.lastname: Lew
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019643:Arthroplasty, Replacement; D002986:Clinical Trials as Topic; D006801:Humans; D016459:Prosthesis-Related Infections / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery / Q000628:therapy*; D012086:Reoperation
chemical_list: D000900:Anti-Bacterial Agents